Population Pharmacokinetic Evaluation and Missed‐Dose Simulations for Eslicarbazepine Acetate Monotherapy in Patients With Partial‐Onset Seizures
S Sunkaraneni, D Blum, E Ludwig… - … in drug development, 2018 - Wiley Online Library
Given the potential consequences of antiepileptic therapy nonadherence, missed‐dose
scenarios of 12‐to 48‐hour dose delays (4‐hour intervals) for eslicarbazepine acetate …
scenarios of 12‐to 48‐hour dose delays (4‐hour intervals) for eslicarbazepine acetate …
Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures
S Sunkaraneni, E Ludwig, J Fiedler-Kelly… - … of Pharmacokinetics and …, 2018 - Springer
Modeling and simulations were used to support body weight-based dose selection for
eslicarbazepine acetate (ESL) in pediatric subjects aged 4–17 years with partial-onset …
eslicarbazepine acetate (ESL) in pediatric subjects aged 4–17 years with partial-onset …
Population Pharmacokinetics and Exposure–Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial‐Onset Seizures
S Sunkaraneni, EA Ludwig, JA Passarell… - The Journal of …, 2018 - Wiley Online Library
Eslicarbazepine acetate (ESL) is a once‐daily oral antiepileptic drug (AED) indicated for
partial‐onset seizures (POS). ESL pharmacokinetics (PK) and exposure–response analyses …
partial‐onset seizures (POS). ESL pharmacokinetics (PK) and exposure–response analyses …
Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
S Sunkaraneni, JA Passarell, EA Ludwig… - Clinical …, 2017 - Taylor & Francis
Purpose Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic drug (AED)
indicated for partial-onset seizures (POS). Clinical studies of gradual conversion to ESL …
indicated for partial-onset seizures (POS). Clinical studies of gradual conversion to ESL …
[PDF][PDF] Pharmacokinetic-Pharmacodynamic Modeling and Simulation to Predict Efficacy Outcomes With Eslicarbazepine Acetate 800 mg Once Daily as Monotherapy …
S Sunkaraneni, JA Passarell, E Ludwig… - JOURNAL OF …, 2016 - simulations-plus.com
Pharmacokinetic-Pharmacodynamic Modeling and Simulation to Predict Efficacy Outcomes
With Eslicarbazepine Acetate 800 mg Once D Page 1 Pharmacokinetic-Pharmacodynamic …
With Eslicarbazepine Acetate 800 mg Once D Page 1 Pharmacokinetic-Pharmacodynamic …
[PDF][PDF] Use of pharmacokinetic-pharmacodynamic modeling and simulations to predict efficacy outcomes with eslicarbazepine acetate 800 mg once daily as …
S Sunkaraneni, JA Passarell, J Pitner, T Grinnell… - 2016 - simulations-plus.com
• The FDA-recommended dose range for ESL maintenance is 800–1600 mg QD. 6 For
patients on ESL monotherapy, a maintenance dose of 800 mg QD should generally be …
patients on ESL monotherapy, a maintenance dose of 800 mg QD should generally be …